抗菌肽Sublancin与黄芪多糖对免疫抑制小鼠免疫功能调节作用的比较分析

doi:10.11843/j.issn.0366-6964.2019.02.019

摘要/Abstract

摘要：

旨在比较研究抗菌肽sublancin与黄芪多糖对环磷酰胺（cyclophosphamide，CTX）诱导的免疫抑制小鼠的免疫功能的调节作用。试验选取60只4~6周龄健康雌性BALB/c小鼠，随机分为6个处理组。正常对照组：第1-3天，腹腔注射生理盐水；第4-10天，灌胃生理盐水。其余五个处理组：第1-3天，腹腔注射CTX（80 mg·kg^-1）；第4-10天，阴性对照组：灌胃生理盐水；低浓度抗菌肽组：灌胃4.0 mg·kg^-1抗菌肽sublancin；高浓度抗菌肽组：灌胃8.0 mg·kg^-1抗菌肽sublancin；黄芪多糖组：灌胃200.0 mg·kg^-1黄芪多糖；阳性对照组：灌胃10.0 mg·kg^-1左旋咪唑。所有处理均为每天一次，每次0.2 mL。于试验第1天小鼠腹腔注射CTX前、第4天灌胃前和第11天对小鼠进行称重。第11天称重结束后，采集全部小鼠的外周血及脾，检测外周血生理生化指标、CD4⁺与CD8⁺数量和脾细胞的细胞因子mRNA表达等指标。结果表明，与正常对照组相比，阴性对照组中小鼠体重、外周血的红细胞、血红蛋白和白细胞含量显著降低（P<0.05），脾IL-2、IL-4和IL-6的基因表达显著降低（P<0.05）。灌胃后，与阴性对照组相比，黄芪多糖组和高浓度sublancin组体重无差异但有升高趋势，说明高浓度sublancin与黄芪多糖对小鼠体重有积极影响；低、高浓度sublancin、黄芪多糖组和阳性对照组中小鼠外周血的白细胞含量显著升高（P<0.05）；高剂量sublancin组中小鼠外周血的红细胞和血红蛋白显著升高；低、高浓度sublancin和黄芪多糖组中小鼠外周血的CD4⁺显著升高（P<0.05）；低、高浓度sublancin、黄芪多糖组和阳性对照组中小鼠外周血的CD8⁺显著降低（P<0.05）；低、高浓度sublancin组中小鼠外周血的CD4⁺/CD8⁺细胞显著升高（P<0.05）；低、高浓度sublancin、黄芪多糖组和阳性对照组中小鼠脾IL-4的表达均显著升高（P<0.05）；高浓度sublancin、黄芪多糖组和阳性对照组中小鼠脾IL-2、IL-6的表达显著升高（P<0.05）。综合上述结果，适宜剂量的抗菌肽sublancin和黄芪多糖均可缓解环磷酰胺造成的免疫抑制。与200.0 mg·kg^-1黄芪多糖相比，8.0 mg·kg^-1抗菌肽sublancin对缓解环磷酰胺免疫抑制造成的细胞因子降低的效果更好。

Abstract:

The purpose of this study was to evaluate the immunomodulatory effects of antimicrobial peptide sublancin and astragalus polysaccharides (APS) on immunosuppressive mice induced by cyclophosphamide (CTX). Sixty healthy female BALB/c mice aged 4-6 weeks were randomly divided into 6 groups of 10 each. Normal control group:d 1 to d 3, intraperitoneally injected with 0.9% physiological saline, d 4 to d 10, gavage 0.9% physiological saline. The other 5 groups:d 1 to d 3, injected with CTX (80 mg·kg^-1). On the d 4 to d 10, the negative control group:gavage 0.9% physiological saline; low or high concentration sublancin treatment group:sublancin solution was administered at a dose of 4.0 and 8.0 mg·kg^-1; the APS-treated group:gavage APS (200 mg·kg^-1); positive control group:gavage levamisole (10 mg·kg^-1, BW). All treatments were performed once a day and 0.2 mL each time. The mice were weighed before the mice were intraperitoneally injected with CTX on the first day of the experiment, on the d 4 before gavage and on the d 11. After weighing the body weight on the d 11, peripheral blood and spleen were collected. Compared with the normal control group, the peripheral blood red blood cell, hemoglobin, and white blood cell counts in the negative control group were significantly reduced (P<0.05); the gene expression of IL-2, IL-4, and IL-6 in the spleen was significantly reduced (P<0.05). Compared with the negative control group, there was no difference in body weight between the APS group and the high concentration Sublancin group after intragastric administration but there is an upward trend, indicating that high concentration Sublancin and APS had a positive effect on body weight of mice; the leukocyte content in peripheral blood of low and high concentration Sublancin, APS, and positive control groups were significantly increased (P<0.05); in the high concentration Sublancin-treated group, red blood cells and hemoglobin were significantly increased (P<0.05); CD4⁺ levels in peripheral blood of mice treated with low or high concentration Sublancin and APS were significantly increased (P<0.05); in both low and high concentration Sublancin, APS and positive control groups, CD8⁺ was significantly decreased (P<0.05); in low and high concentration sublancin groups, CD4⁺/CD8⁺ was significantly increased (P<0.05); in low and high concentration sublancin, APS and positive control groups, mouse spleen IL-4 were significantly increased (P<0.05); in high concentration sublancin, APS and positive control groups, the expressions of IL-2 and IL-6 in the spleen of mice were significantly increased (P<0.05). In summary, it can be concluded that appropriate doses of the antimicrobial peptides sublancin and APS can all alleviate the immunosuppression caused by cyclophosphamide. Compared with APS, the role of antimicrobial peptide sublancin in the effect on alleviating the immunosuppression of CTX is more comprehensive.

中图分类号:

S852.4

尚丽君, 杨天任, 于海涛, 黄烁, 曾祥芳, 谯仕彦. 抗菌肽Sublancin与黄芪多糖对免疫抑制小鼠免疫功能调节作用的比较分析[J]. 畜牧兽医学报, 2019, 50(2): 406-414.

SHANG Lijun, YANG Tianren, YU Haitao, HUANG Shuo, ZENG Xiangfang, QIAO Shiyan. Immunomodulation Effect of Antimicrobial Peptide Sublancin and Astragalus Polysaccharides on Immunosuppressed Mice: A Comparative Study[J]. ACTA VETERINARIA ET ZOOTECHNICA SINICA, 2019, 50(2): 406-414.

参考文献

[1] ZASLOFF M. Antimicrobial peptides of multicellular organisms[J]. Nature, 2002, 415(6870):389-395.
[2] LAI Y P, GALLO R L. AMPed up immunity:how antimicrobial peptides have multiple roles in immune defense[J]. Trends Immunol, 2009, 30(3):131-141.
[3] MANSOUR S C, PENA O M, HANCOCK R E W. Host defense peptides:front-line immunomodulators[J]. Trends Immunol, 2014, 35(9):443-450.
[4] PAIK S H, CHAKICHERLA A, HANSEN J N. Identification and characterization of the structural and transporter genes for, and the chemical and biological properties of, sublancin 168, a novel lantibiotic produced by Bacillus subtilis 168[J]. J Biol Chem, 1998, 273(36):23134-23142.
[5] KOUWEN T R H M, TRIP E N, DENHAM E L, et al. The large mechanosensitive channel MscL determines bacterial susceptibility to the bacteriocin sublancin 168[J]. Antimicrob Agents Chemother, 2009, 53(11):4702-4711.
[6] 王帅. 抗菌肽Sublancin对肉鸡坏死性肠炎和小鼠天然免疫的影响[D]. 北京:中国农业大学, 2017.
WANG S. Effects of antimicrobial peptide Sublancin on necrotic enteritis of broilers and the innate immunity of mice[D]. Beijing:China Agricultural University, 2017. (in Chinese)
[7] 张小梅. 黄芪多糖的免疫调节作用及抗肿瘤作用研究进展[J]. 大连大学学报, 2003, 24(6):101-104.
ZHANG X M. Advances in the immunomodulatory effects and anti-tumor effects of Astragalus polysaccharides[J]. Journal of Dalian University, 2003, 24(6):101-104. (in Chinese)
[8] LIU Q Y, YAO Y M, YU Y, et al. Astragalus polysaccharides attenuate postburn sepsis via inhibiting negative immunoregulation of CD4⁺ CD25^high T cells[J]. PLoS One, 2011, 6(7):e19811.
[9] JIANG R Z, WANG Y, LUO H M, et al. Effect of the molecular mass of tremella polysaccharides on accelerated recovery from cyclophosphamide-induced leucopenia in rats[J]. Molecules, 2012, 17(12):3609-3617.
[10] HATTA H, TSUDA K, AKACHI S, et al. Productivity and some properties of egg yolk antibody (IgY) against human rotavirus compared with rabbit IgG[J]. Biosci Biotechnol Biochem, 1993, 57(3):450-454.
[11] PICHEL N, VIVARB M. Origin of thyroid dysfunction at the Saharawi refugee camps[J]. J Trace Elem Med Biol, 2018, 48:57.
[12] LIAO W, LIN J X, LEONARD W J. IL-2 family cytokines:new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation[J]. Curr Opin Immunol, 2011, 23(5):598-604.
[13] PARK H Y, YU A R, CHOI I W, et al. Immunostimulatory effects and characterization of a glycoprotein fraction from rice bran[J]. Int Immunopharmacol, 2013, 17(2):191-197.
[14] TZIANABOS A O. Polysaccharide immunomodulators as therapeutic agents:structural aspects and biologic function[J]. Clin Microbiol Rev, 2000, 13(4):523-533.
[15] 李波,韩文瑜,宋智娟,等. 抗菌肽的免疫调节活性及其在动物生产中的应用[J]. 中国饲料, 2014(4):14-17.
LI B, HAN W Y, SONG Z J, et al. Immunoregulatory of antimicrobial peptide and its application in animal production[J]. China Feed, 2014(4):14-17. (in Chinese)
[16] WANG S, WANG Q W, ZENG X F, et al. Use of the antimicrobial peptide Sublancin with combined antibacterial and immunomodulatory activities to protect against methicillin-resistant Staphylococcus aureus infection in mice[J]. J Agric Food Chem, 2017, 65(39):8595-8605.
[17] LIU Y, ZHANG S F, ZHANG F, et al. Adjuvant activity of Chinese herbal polysaccharides in inactivated veterinary rabies vaccines[J]. Int J Biol Macromol, 2012, 50(3):598-602.
[18] 赵弋清,罗霞,陈东辉,等. 不同剂量环磷酰胺诱导正常小鼠免疫抑制的对比研究[J]. 免疫学杂志, 2005, 21(3):122-124, 128.
ZHAO Y Q, LUO X, CHEN D H, et al. Comparison of immunosuppression induced by different doses of cyclophosphamide in normal mice[J]. Immunological Journal, 2005, 21(3):122-124, 128. (in Chinese)
[19] EL-ABASY M, MOTOBU M, NAKAMURA K, et al. Preventive and therapeutic effects of sugar cane extract on cyclophosphamide-induced immunosuppression in chickens[J]. Int Immunopharmacol, 2004, 4(8):983-990.
[20] CRUZ-CHAMORRO L, PUERTOLLANO M A, PUERTOLLANO E, et al. Examination of host immune resistance against Listeria monocytogenes infection in cyclophosphamide-treated mice after dietary lipid administration[J]. Clin Nutrit, 2007, 26(5):631-639.
[21] ATSAMO A D, NGUELEFACK T B, DATTÉ J Y, et al. Acute and subchronic oral toxicity assessment of the aqueous extract from the stem bark of Erythrina senegalensis DC (Fabaceae) in rodents[J]. J Ethnopharmacol, 2011, 134(3):697-702.
[22] SHEEJA K, KUTTAN G. Ameliorating effects of Andrographis paniculata extract against cyclophosphamide-induced toxicity in mice[J]. Asian Pac J Cancer Prev, 2006, 7(4):609-614.
[23] SHALIT I, KLETTER Y, HALPERIN D, et al. Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia[J]. Eur J Haematol, 2001, 66(5):287-296.
[24] BERGER M, LANINO E, CESARO S, et al. Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies:an AIEOP-GITMO retrospective multicenter study[J]. Biol Blood Marrow Transplant, 2016, 22(5):902-909.
[25] ZHAO L, ASHRAF M A. Influence of silver-hydroxyapatite nanocomposite coating on biofilm formation of joint prosthesis and its mechanism[J]. West Indian Med J, 2015, 64(5):506-513.
[26] TINDEMANS I, SERAFINI N, DI SANTO J P, et al. GATA-3 function in innate and adaptive immunity[J]. Immunity, 2014, 41(2):191-206.
[27] LIU Q, YU S, LI A, et al. Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment[J]. Tumour Biol, 2017, 39(6):1010428317712445.
[28] NAKA T, NISHIMOTO N, KISHIMOTO T. The paradigm of IL-6:from basic science to medicine[J]. Arthritis Res, 2002, 4(S3):S233-S242.
[29] TANIGUCHI K, KARIN M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer[J]. Semin Immunol, 2014, 26(1):54-74.
[30] GUTHRIE G J K, ROXBURGH C S D, RICHARDS C H, et al. Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer[J]. Br J Cancer, 2013, 109(1):131-137.
[31] HOU H, FAN Y, WANG S K, et al. Immunomodulatory activity of Alaska pollock hydrolysates obtained by glutamic acid biosensor-Artificial neural network and the identification of its active central fragment[J]. J Funct Foods, 2016, 24:37-47.
[32] 张琰,程建峰,贺建荣,等. 黄芪多糖对环磷酰胺致小鼠骨髓抑制及毒性的保护作用[J]. 第四军医大学学报, 2003, 24(5):447-448.
ZHANG Y, CHENG J F, HE J R, et al. Protection of astragalus polyaaccharidcs on toxicity and bone marrow inhibition caused by cyclophosphamide[J]. Journal of the Fourth Military Medical University, 2003, 24(5):447-448. (in Chinese)
[33] ZHU Y L, WANG L Y, WANG J X, et al. Protective effects of paeoniflorin and albiflorin on chemotherapy-induced myelosuppression in mice[J]. Chin J Nat Med, 2016, 14(8):599-606.
[34] 徐尚福,杨天华,吴芹,等. 黄芪多糖对环磷酰胺引起小鼠骨髓抑制后造血功能的修复作用[J]. 遵义医学院学报, 2011, 34(5):473-476.
XU S F, YANG T H, WU Q, et al. Restorative effect of astragalus polysaccharides on hematopoietic function in cyclophosphamide-induced bone marrow depression in mice[J]. Acta Academiae Medicinae Zunyi, 2011, 34(5):473-476. (in Chinese)
[35] 李秀,初杰,李影迪,等. 当归/黄芪多糖对腹腔注射环磷酰胺小鼠骨髓造血影响随机平行对照研究[J]. 实用中医内科杂志, 2017, 31(5):52-58.
LI X, CHU J, LI Y D, et al. Angelica sinensis/astragalus polysaccharides on hematopoietic function of bone barrow of mice induced by intraperitoneal injection of cyclophosphamide impact a randomized parallel controlled study[J]. Journal of Practical Traditional Chinese Internal Medicine, 2017, 31(5):52-58. (in Chinese)
[36] SYRJÄLÄ H, SURCEL H M, ILONEN J. Low CD4/CD8 T lymphocyte ratio in acute myocardial infarction[J]. Clin Exp Immunol, 1991, 83(2):326-328.
[37] MCBRIDE J A, STRIKER R. Imbalance in the game of T cells:what can the CD4/CD8 T-cell ratio tell us about HIV and health?[J]. PLoS Pathog, 2017, 13(11):e1006624.
[38] TAKEUCHI A, ETO M, YAMADA H, et al. A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice[J]. Int J Cancer, 2012, 130(2):365-376.
[39] LIU P, JAFFAR J, HELLSTROM I, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice[J]. J Immunother, 2010, 33(1):53-59.
[40] GHIRINGHELLI F, LARMONIER N, SCHMITT E, et al. CD4⁺ CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative[J]. Eur J Immunol, 2004, 34(2):336-344.
[41] HONG S H, YOON I H, KIM Y H, et al. High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44^high cells after their selective depletion[J]. Immunobiology, 2010, 215(3):182-193.
[42] BRODE S, RAINE T, ZACCONE P, et al. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells[J]. J Immunol, 2006, 177(10):6603-6612.
[43] LUTSIAK M E, SEMNANI R T, DE RASCALIS P, et al. Inhibition of CD4⁺ 25⁺ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide[J]. Blood, 2005, 105(7):2862-2868.